Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
Conditions
Keywords
squamous cell carcinoma, esthesioneuroblastoma, adenoid cystic carcinoma, adenocarcinoma, cisplatin, 17-442
Brief summary
This study is being done to test a new treatment plan for large tumors in the sinus or nasal cavity that will include endoscopic surgery plus chemotherapy and proton-beam radiation therapy.
Interventions
DRUGCisplatin
Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)
RADIATIONAdjuvant Proton Radiotherapy
Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology.
PROCEDUREEndoscopic Resection
In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age greater than or equal to 18 years. * Histopathologically confirmed diagnosis of one the following cancer types: * Squamous cell carcinoma * Esthesioneuroblastoma * Adenoid cystic carcinoma * Adenocarcinoma * Paranasal sinus/nasal cavity malignancy is considered unresectable with negative margins surgery or resection would be considered excessively morbid. This could include lesions with: * Carotid involvement * Cavernous sinus invasion * Brain invasion * Orbital apex * Intraconal space * Pterygoid musculature involvement * Invasion of the clivus * Resection of at least 80% of the volume of the tumor is feasible. Resectability will be determined by the surgeon and radiologist after discussion among the multidisciplinary team. For patients who have had surgery at an outside institution, the same parameters will be thoroughly screened to ensure the patient met the same inclusion criteria and resection standards. * Patients must be a candidate for surgery (as per treating surgeon) and be able to tolerate proton radiation and chemotherapy (as per treating radiation oncologist and medical oncologist). * Karnofsky performance statue \>/= 70 * The subject has organ and marrow function and laboratory values rendering safe administration of Cisplatin: * The ANC \>/= 1000/mm3 without colony stimulating factor support * Platelets \>/= 100,000/mm3 * Hemoglobin \>/= 9 g/dL * Bilirubin \</= 1.5 mg/dL the ULM. For subjects with Gilbert's disease, bilirubin \</= 3.0 mg/dL * Serum albumin \>/= 2.8 g/dl * Creatinine clearance (CrCl) \>/= 60 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used: * Male: CrCl (mL/min) = (140 = age) x wt (kg) / (serum creatinine x 72) * Female: Multiply above result by 0.85 * ALT and AST \</= 3.0 ULN * Serum phosphorus, calcium, magnesium and potassium \>/= LLN * No evidence of intercurrent infection * Negative pregnancy test for women of childbearing potential (\<51 years of age) as per institutional policy. * Patients with distant metastatic disease may not be included. * Patient must be able to read and write in English. * Patients who intitially meet the histopathological inclusion criteria but surgical pathology report shows Sinonasal Undifferentiated Carcinoma.
Exclusion criteria
* Tumor is deemed to be resectable with negative margins by conventional surgical standards. * Patients not able to receive standard-dose cisplatin based on the judgement of the treating medical oncologist. * Patients with chronic kidney disease (GFR \<60), uncontrolled hypertension, congestive heart failure, pre-existing bone marrow dysfunction, or cytopenias. ° Congestive heart failure (CHF): New York Heart Association (NYHA) Class II-IV at the time of screening * Concurrent uncontrolled hypertension defined as sustained blood pressure \> 150 mm Hg systolic or \> 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment; If severe hearing impairment is measured or if significant neuropathy is reported at baseline the treating physician will discuss the risks for further permanent hearing loss and neuropathy with the patient. * Patients not able to have a MRI (due to pacemaker, claustrophobia, etc.). * Inability to return to MSKCC for frequent scheduled hydration sessions post-chemotherapy. * Inability to comply with requirements for cisplatin administration anti-emetic regimens post-treatment. * Patients not able or unwilling to travel for proton therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors | 1 year | Assessment of local control after near-total endoscopic resection (NTR) followed by concurrent chemotherapy with proton-beam radiation in unresectable tumors (which we define as expected inability to perform negative margin surgery) of the paranasal sinuses and nasal cavity. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Unresectable Paranasal Sinus/Nasal Cavity Malignancy cisplatin and etoposide | 3 |
| Total | 3 |
Baseline characteristics
| Characteristic | Unresectable Paranasal Sinus/Nasal Cavity Malignancy |
|---|---|
| Age, Continuous | 60 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 1 Participants |
| Region of Enrollment United States | 3 Participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 3 |
| other Total, other adverse events | 0 / 3 |
| serious Total, serious adverse events | 0 / 3 |
Outcome results
Primary
Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors
Assessment of local control after near-total endoscopic resection (NTR) followed by concurrent chemotherapy with proton-beam radiation in unresectable tumors (which we define as expected inability to perform negative margin surgery) of the paranasal sinuses and nasal cavity.
Time frame: 1 year
Population: N/A - data were not collected